FDA OKs Milsaperidone for Bipolar I Disorder, Schizophrenia FDA OKs Milsaperidone for Bipolar I Disorder, Schizophrenia
February 23, 2026GP Partnership Appeal Slumps, Survey Finds GP Partnership Appeal Slumps, Survey Finds
February 23, 2026
Today, Eli Lilly launched a four-dose, single-patient use KwikPen device for its injectable obesity drug, tirzepatide (Zepbound).
The device gives patients an additional, potentially more convenient option for taking the drug: They can use one KwikPen to take four weekly doses instead of four single-dose vials. The FDA opened the door for the new tirzepatide delivery device when it approved a label expansion for the drug.
Patients with a prescription who self-pay can receive all doses in a KwikPen or single-dose vials through LillyDirect, the company’s direct-to-consumer website. Prices start at $299 per month for the 2.5 mg dose.
New prescribing information for Zepbound includes the KwikPen, noting it’s not for use by patients with visual impairments. Clinicians are also advised not to share a Zepbound KwikPen between patients even if the needle is changed to avoid the risk of blood-borne pathogens.
Marilynn Larkin, MA, is an award-winning medical writer and editor whose work has appeared in numerous publications, including Medscape Medical News and its sister publication MDedge, The Lancet (where she was a contributing editor), and Reuters Health.
